Foresite Capital Management IV
$290M 13F equity value
9 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Foresite Capital Management IV covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| PHVS | Pharvaris N.V. | 4,778,581 | $165M | 57.0% |
| CYTK | CYTOKINETICS INC | 714,695 | $61M | 21.0% |
| EIKN | Eikon Therapeutics, Inc. | 1,943,682 | $25M | 8.7% |
| RLAY | Relay Therapeutics, Inc. | 1,250,000 | $23M | 8.1% |
| XENE | Xenon Pharmaceuticals Inc. | 160,000 | $10M | 3.3% |
| CRNX | Crinetics Pharmaceuticals, Inc. | 150,000 | $6M | 1.9% |
| ALEC | Alector, Inc. | |||
| LYEL | Lyell Immunopharma, Inc. | |||
| MAZE | Maze Therapeutics, Inc. |
Track Foresite Capital Management IV's 13F portfolio: $290M in reported holdings, 9 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}